Chara Biologics FDA Warning Letter | Stem Cell & Exosome Investigation
FDA issued a January 2025 warning letter to Chara Biologics over CharaExo, CharaCore, and CharaOmni. Learn what the letter found, prior 2019 notice, and key regulatory issues.
Taking the first step doesn’t have to be complicated. In just a few minutes, you can share the basics of your case, and our team will guide you from there: